Source-grounded facts extracted from ARROWHEAD PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ARROWHEAD PHARMACEUTICALS, INC. reported financial results for fiscal 2026 second quarter ended March 31, 2026.
“Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.”
ARROWHEAD PHARMACEUTICALS, INC. entered into underwriting agreement with J.P. Morgan Securities LLC and Jefferies LLC as representatives of the several underwriters valued at an additional $75,000,000 aggregate principal amount of Notes (effective 2026-01-12).
“Pursuant to an underwriting agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Underwriters”), the Company granted the Underwriters an option, which is exercisable within 30 days after January 7, 2026, to purchase up to an additional $75,000,000 aggregate principal amount of Notes solely to cover over-allotments.”
ARROWHEAD PHARMACEUTICALS, INC. entered into Indenture with U.S. Bank Trust Company, National Association valued at $700,000,000 aggregate principal amount (effective 2026-01-12).
“On January 12, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) issued $700,000,000 aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of January 12, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture”
ARROWHEAD PHARMACEUTICALS, INC. entered into Convertible Notes Underwriting Agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters valued at $625,000,000 aggregate principal amount (effective 2026-01-07).
“On January 7, 2026, the Company entered into an underwriting agreement (the “Convertible Notes Underwriting Agreement”) with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters named therein (the “Convertible Notes Underwriters”), to issue and sell (the “Convertible Notes Offering”) $625,000,000 aggregate principal amount of its 0.00% convertible senior notes due 2032”
ARROWHEAD PHARMACEUTICALS, INC. entered into Equity Underwriting Agreement with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters (effective 2026-01-07).
“On January 7, 2026, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Jefferies LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein (collectively, the “Equity Underwriters”), to issue and sell 3,100,776 shares of the Company’s common stock”
Daniel Apel was appointed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..
“the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company”
Ken Myszkowski departed as Chief Financial Officer at ARROWHEAD PHARMACEUTICALS, INC..
“Ken Myszkowski notified Arrowhead Pharmaceuticals, Inc. (the “Company”) of his decision to retire as Chief Financial Officer of the Company, effective as of May 13, 2025”
Douglas Ingram was appointed as director at ARROWHEAD PHARMACEUTICALS, INC..
“On February 5, 2025, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Douglas Ingram as a director of the Company, effective February 6, 2025.”
ARROWHEAD PHARMACEUTICALS, INC. reported Fiscal 2024 second quarter (three months ended March 31, 2024) results: net income Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300), EPS Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.02).
“OPERATING SUMMARY 2024 2023 (Unaudited) Revenue $ — $ 146,267 Operating Expenses: Research and development 101,122 74,881 General and administrative expenses 25,069 23,221 Total Operating Expenses 126,191 98,102 Operating (loss) income (126,191) 48,165 Total other expense (805) (489) (Loss) income before income tax expense and noncontrolling interest (126,996) 47,676 Income tax expense — — Net (loss) income including noncontrolling interest (126,996) 47,676 Net (loss) income attributable to noncontrolling interest, net of tax (1,696) (999) Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. $ (125,300) $ 48,675 Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted $ (1.02) $ 0.45”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Ratification of KPMG as independent auditors. at the 2024-03-14 meeting.
“Ratification of KPMG as Independent Auditors of the Company 104,057,945 FOR 2,562,563 AGAINST 365,912 ABSTAIN 0 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation. at the 2024-03-14 meeting.
“Advisory Vote to Approve Executive Compensation 82,576,047 FOR 4,950,419 AGAINST 143,385 ABSTAIN 19,316,569 NON VOTES”
ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Election of seven directors to serve until next annual meeting. at the 2024-03-14 meeting.
“Election of Directors NAME FOR AGAINST ABSTAIN NON VOTES Douglass Given 76,397,567 10,968,346 303,938 19,316,569 Michael S. Perry 82,446,900 4,911,855 311,096 19,316,569 Christopher Anzalone 84,313,696 2,976,660 379,495 19,316,569 Mauro Ferrari 81,342,884 6,020,799 306,168 19,316,569 Adeoye Olukoton 83,526,809 3,815,731 327,311 19,316,569 William Waddill 83,279,633 4,079,251 310,967 19,316,569 Victoria Vakiener 83,354,988 3,975,617 339,246 19,316,569”
Hongbo Lu was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
“Appointment of Hongbo Lu as a Director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.